Evaluating a new vaccine for Salmonella infections

A Phase 1/2a, Observer-blind, Randomized, Controlled, Two-stage, Multi-country Study to Evaluate the Safety, Reactogenicity, and Immune Response of the Trivalent Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) and Typhoid Fever in Healthy European and African Adults

This study is testing a new vaccine for Salmonella infections in healthy adults to see if it is safe and how well it works.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 155 (estimated)
• Ages: 18 Years to 50 Years
• Sex: All
• Sponsor: GlaxoSmithKline (Industry-sponsored)
• Drugs / interventions: infliximab, prednisone
• Locations: 2 sites (Edegem and 1 other locations)
• Trial ID: NCT05480800 on ClinicalTrials.gov

What this trial studies

This study aims to assess the safety, reactogenicity, and immune response of the invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) in healthy adults. The trial will be conducted in two stages, starting with European adults followed by African adults. Participants will receive different doses of the vaccine to evaluate its effectiveness and safety profile. The study is sponsored by GlaxoSmithKline and involves collaboration with several health organizations.

Who should consider this trial

Good fit: Ideal candidates for this study are healthy adults aged 18 to 50 years.

Not a fit: Patients with underlying health conditions or those outside the specified age range may not benefit from this study.

Why it matters

Potential benefit: If successful, this vaccine could significantly reduce the incidence of invasive nontyphoidal Salmonella and typhoid fever, improving public health outcomes.

How similar studies have performed: Other studies have shown promise in vaccine development for Salmonella, but this specific approach is novel.

Eligibility criteria

Inclusion criteria

* Participants, who, in the opinion of the Investigator, can and will comply with the requirements of the protocol.
* Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study-specific procedure.
* Healthy participants as established by medical history, clinical examination, and laboratory assessment.
* Participant satisfying screening requirements.
* A male or female between and including 18 and 50 years of age at the time of the first study intervention administration.
* Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy, or post-menopause.
* Female participants of childbearing potential may be enrolled in the trial if the participant:
* Has practiced adequate contraception for 1 month prior to study intervention administration, and
* Has a negative pregnancy test on the day of study intervention administration, and
* Has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.
* Blood sample for simultaneous follicle-stimulating hormone (FSH) and estradiol levels may be collected at the discretion of the Investigator to confirm non-reproductive potential according to local laboratory reference range.
* Genetic testing for HLA-B27 will be performed at Screening and only participants with a negative result will be allowed to participate in the study\*.

  * Only for Stage 1.
* For Malawi (Stage 2), the participant lives in Blantyre and has agreed to remain in Blantyre for the study duration.

Exclusion criteria Medical Conditions

* Known exposure to S. Typhi and nontyphoidal Salmonella confirmed by blood culture during the period starting 3 years prior to first study intervention administration confirmed using past medical history.
* History of any reaction or hypersensitivity associated with any component of the study interventions.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests.
* Recurrent history or uncontrolled neurological disorders or seizures.
* Any clinically significant\* hematological and/or biochemical laboratory abnormality.

  * The Investigator should use his/her clinical judgment to decide which abnormalities are clinically significant from the panel of tests in the list of safety assays.
* Clinical conditions representing a contraindication to IM injections and/or blood draws.
* Any behavioral or cognitive impairment or psychiatric disease that in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.
* Confirmed positive COVID-19 polymerase chain reaction or lateral flow test during the period starting 28 days before the first administration of study vaccines (Day -28 to Day 1).
* Acute or chronic illness which may be severe enough to preclude participation.
* Any other clinical condition that, in the opinion of the Investigator, might pose additional risk to the participant due to participation in the study.
* All medical conditions will be assessed by the Investigator who may use his/her discretion to decide if the participant meets the exclusion criteria.

Prior/Concomitant Therapy

* History of receiving any typhoid vaccine (Ty21a, Vi capsular polysaccharide, or TCV) in the participant's life.
* History of receiving any investigational iNTS or GMMA vaccines in the participant's life.
* Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days (Days -30 to 1) before the first dose of study interventions, or their planned use during the study period.
* A vaccine not foreseen by the study protocol administered during the period starting at 14 days before the first dose and ending 28 days after the last dose of study interventions administration\*, with the exception of flu vaccines or COVID-19 vaccine.

  * In case emergency mass vaccination for an unforeseen public health threat (eg, a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.

When regulations allow, the recommended time intervals for administration of these vaccines are at least 7 days before or 7 days after (at least 14 days before or 14 days after in case of live vaccines) each dose of study intervention administration.

* Administration of long-acting immune-modifying drugs at any time during the study period (eg, infliximab).
* Administration of Ig and/or any blood products or plasma derivatives during the period starting 3 months before the administration of the first dose of study interventions or planned administration during the study period.
* Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune modifying drugs during the period starting 3 months prior to the first study intervention dose(s). For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants. Inhaled and topical steroids are allowed.

Prior/Concurrent Clinical Study Experience

- Concurrently participating in another clinical trial, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (vaccine and drug).

Other Exclusions

* Pregnant or lactating female
* Female planning to become pregnant or planning to discontinue contraceptive precautions
* History of/current chronic alcohol consumption and/or drug abuse. This will be decided at the discretion of the Investigator. Chronic alcohol consumption is defined as one or more of the following:
* A prolonged period of frequent and heavy alcohol use
* The inability to control drinking once it has begun
* Physical dependence manifested by withdrawal symptoms when the individual stops using alcohol
* Tolerance or the need to use increasing amounts of alcohol to achieve the same effects
* A variety of social and/or legal problems arising from alcohol use.
* Any study personnel or their immediate dependents, family, or household members.

Where this trial is running

Edegem and 1 other locations

• GSK Investigational Site — Edegem, Belgium (Recruiting)
• GSK Investigational Site — Blantyre 3, Malawi (Recruiting)

Study contacts

• Study coordinator: US GSK Clinical Trials Call Center

Conditions Salmonella Infections